JP2016053057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016053057A5 JP2016053057A5 JP2015214045A JP2015214045A JP2016053057A5 JP 2016053057 A5 JP2016053057 A5 JP 2016053057A5 JP 2015214045 A JP2015214045 A JP 2015214045A JP 2015214045 A JP2015214045 A JP 2015214045A JP 2016053057 A5 JP2016053057 A5 JP 2016053057A5
- Authority
- JP
- Japan
- Prior art keywords
- angiotensin
- drug
- product according
- diabetic nephropathy
- drug product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940126534 drug product Drugs 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000005541 ACE inhibitor Substances 0.000 claims 5
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 5
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 5
- 239000003087 receptor blocking agent Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 4
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 4
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 4
- 229950010993 atrasentan Drugs 0.000 claims 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 230000000877 morphologic effect Effects 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims 1
- 206010001580 Albuminuria Diseases 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 claims 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229960004064 bumetanide Drugs 0.000 claims 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960002155 chlorothiazide Drugs 0.000 claims 1
- 229960001523 chlortalidone Drugs 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 229960003883 furosemide Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- 229960004569 indapamide Drugs 0.000 claims 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229960002817 metolazone Drugs 0.000 claims 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims 1
- 229960005170 moexipril Drugs 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960002582 perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- 229960005483 polythiazide Drugs 0.000 claims 1
- 229920000046 polythiazide Polymers 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 229960000651 tasosartan Drugs 0.000 claims 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960005461 torasemide Drugs 0.000 claims 1
- 229960002051 trandolapril Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95730007P | 2007-08-22 | 2007-08-22 | |
| US60/957,300 | 2007-08-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183975A Division JP2014001234A (ja) | 2007-08-22 | 2013-09-05 | 糖尿病の合併症のための療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017035751A Division JP2017145251A (ja) | 2007-08-22 | 2017-02-28 | 糖尿病の合併症のための療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016053057A JP2016053057A (ja) | 2016-04-14 |
| JP2016053057A5 true JP2016053057A5 (enExample) | 2016-07-14 |
Family
ID=40220116
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522066A Pending JP2010536880A (ja) | 2007-08-22 | 2008-08-22 | 糖尿病の合併症のための療法 |
| JP2013183975A Pending JP2014001234A (ja) | 2007-08-22 | 2013-09-05 | 糖尿病の合併症のための療法 |
| JP2014198604A Pending JP2015028062A (ja) | 2007-08-22 | 2014-09-29 | 糖尿病の合併症のための療法 |
| JP2015214045A Pending JP2016053057A (ja) | 2007-08-22 | 2015-10-30 | 糖尿病の合併症のための療法 |
| JP2017035751A Pending JP2017145251A (ja) | 2007-08-22 | 2017-02-28 | 糖尿病の合併症のための療法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522066A Pending JP2010536880A (ja) | 2007-08-22 | 2008-08-22 | 糖尿病の合併症のための療法 |
| JP2013183975A Pending JP2014001234A (ja) | 2007-08-22 | 2013-09-05 | 糖尿病の合併症のための療法 |
| JP2014198604A Pending JP2015028062A (ja) | 2007-08-22 | 2014-09-29 | 糖尿病の合併症のための療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017035751A Pending JP2017145251A (ja) | 2007-08-22 | 2017-02-28 | 糖尿病の合併症のための療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US20090054473A1 (enExample) |
| EP (2) | EP2545920A1 (enExample) |
| JP (5) | JP2010536880A (enExample) |
| CA (2) | CA2904447C (enExample) |
| WO (1) | WO2009026517A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| CA2695259C (en) | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| CA2904447C (en) * | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| CN101632672B (zh) * | 2008-07-24 | 2011-01-12 | 鲁南制药集团股份有限公司 | 一种用于治疗高血压的复方药物组合物 |
| WO2010127197A2 (en) * | 2009-04-30 | 2010-11-04 | Midwestern University | Method and composition for treating diabetic ketoacidosis |
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| JP2016521279A (ja) | 2013-04-30 | 2016-07-21 | アッヴィ・インコーポレイテッド | アトラセンタンを使用して脂質プロファイルを改善するための方法 |
| JO3624B1 (ar) * | 2014-05-08 | 2020-08-27 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| AU2015342929A1 (en) * | 2014-11-07 | 2017-05-25 | Abbvie Inc. | Methods of treating CKD using predictors of fluid retention |
| JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| US10369156B2 (en) * | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| MX2019008813A (es) | 2017-01-25 | 2020-02-12 | The George Inst For Global Health | Composiciones para el tratamiento de la hipertension. |
| AU2017400276B2 (en) * | 2017-02-27 | 2024-01-11 | Idorsia Pharmaceuticals Ltd | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
| US20190260657A1 (en) * | 2018-02-21 | 2019-08-22 | Cisco Technology, Inc. | In-band performance loss measurement in ipv6/srv6 software defined networks |
| BR112020022395A2 (pt) * | 2018-05-03 | 2021-04-13 | Midwestern University | Alterações em receptores de endotelina em seguida a hemorragia e ressuscitação por centaquina |
| WO2019226417A1 (en) * | 2018-05-23 | 2019-11-28 | University Of Miami | Methods of treating renal disease associated with chronic kidney disease such as alport syndrome |
| EP3826633A4 (en) * | 2018-07-26 | 2022-04-27 | The George Institute For Global Health | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION |
| EP4094759A1 (en) * | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| CN116327758A (zh) | 2019-12-17 | 2023-06-27 | 奇努克医疗公司 | 用阿曲生坦治疗IgA肾病的方法 |
| CN115803028A (zh) | 2020-07-10 | 2023-03-14 | 阿斯利康(瑞典)有限公司 | 用于治疗慢性肾病的齐泊腾坦和达格列净的组合 |
| EP4329753A4 (en) | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
| CN116804048B (zh) * | 2023-02-24 | 2024-11-15 | 中国农业大学 | 豌豆白蛋白分离肽、组合物及其用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ285522B6 (cs) * | 1993-06-24 | 1999-08-11 | Eli Lilly And Company | Farmaceutický prostředek pro snížení koncentrace glukosy v krvi |
| FI943071A7 (fi) * | 1993-06-24 | 1994-12-25 | Takeda Chemical Industries Ltd | Anti-endoteliiniainetta pysyvästi vapauttava valmiste |
| US7208517B1 (en) * | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US5767144A (en) * | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| DE69527072T2 (de) | 1994-08-19 | 2003-02-13 | Abbott Laboratories, Abbott Park | Endothelin antagoniste |
| US6162927A (en) * | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) * | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| NZ330818A (en) | 1996-02-13 | 2000-05-26 | Abbott Lab | Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
| US6420412B2 (en) * | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
| US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| TR200101234T2 (tr) | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| US7445792B2 (en) * | 2003-03-10 | 2008-11-04 | Abbott Laboratories | Medical device having a hydration inhibitor |
| EP1014989B1 (de) | 1997-09-26 | 2004-01-14 | Abbott GmbH & Co. KG | Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate |
| US8257725B2 (en) * | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| DE19743140A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19743142A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19743143A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19744799A1 (de) | 1997-10-10 | 1999-04-15 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19754082A1 (de) | 1997-12-05 | 1999-06-10 | Knoll Ag | Methode zur Bekämpfung der Fettleibigkeit |
| EP1114022A1 (en) | 1998-09-14 | 2001-07-11 | Abbott Laboratories | Process for producing stereoselective nitro compounds |
| US8257724B2 (en) * | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| US6238708B1 (en) * | 1999-02-23 | 2001-05-29 | The Iams Company | Composition and process for controlling glucose metabolism in companion animals by dietary starch |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| US20020055457A1 (en) * | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| EP1379238A1 (en) | 2001-04-11 | 2004-01-14 | Abbott Laboratories | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US20030022811A1 (en) * | 2001-04-11 | 2003-01-30 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US20030092757A1 (en) * | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| BR0212899A (pt) * | 2001-09-21 | 2004-11-03 | Novartis Ag | Compostos orgânicos |
| CN100341496C (zh) * | 2002-03-22 | 2007-10-10 | 橘生药品工业株式会社 | 预防或治疗肾脏疾病的药剂 |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| CL2004000545A1 (es) | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
| ATE400297T1 (de) * | 2004-02-11 | 2008-07-15 | Fibrogen Inc | Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie |
| NZ586285A (en) * | 2004-03-17 | 2011-12-22 | Novartis Ag | Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X) |
| JP4949227B2 (ja) * | 2004-03-19 | 2012-06-06 | アボット・ラボラトリーズ | バルーンおよびプロテーゼからの多剤送達 |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| WO2006034084A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| US20060135596A1 (en) * | 2004-09-17 | 2006-06-22 | Zhang Geoff G | Amorphous form of a drug |
| KR20080012304A (ko) * | 2005-05-23 | 2008-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약 |
| US20080132710A1 (en) * | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| CA2904447C (en) * | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| US20100184026A1 (en) * | 2009-01-22 | 2010-07-22 | Abbott Laboratories | Companion Diagnostic Assays For Endothelin Receptor Antagonists |
-
2008
- 2008-08-22 CA CA2904447A patent/CA2904447C/en not_active Expired - Fee Related
- 2008-08-22 CA CA2697057A patent/CA2697057A1/en not_active Abandoned
- 2008-08-22 JP JP2010522066A patent/JP2010536880A/ja active Pending
- 2008-08-22 EP EP12182366A patent/EP2545920A1/en not_active Withdrawn
- 2008-08-22 US US12/196,635 patent/US20090054473A1/en not_active Abandoned
- 2008-08-22 EP EP08798489A patent/EP2190433A2/en not_active Withdrawn
- 2008-08-22 WO PCT/US2008/074013 patent/WO2009026517A2/en not_active Ceased
-
2013
- 2013-02-13 US US13/766,266 patent/US8623819B2/en active Active
- 2013-09-05 JP JP2013183975A patent/JP2014001234A/ja active Pending
- 2013-11-13 US US14/079,464 patent/US8865650B2/en active Active
-
2014
- 2014-09-19 US US14/491,479 patent/US9592231B2/en not_active Expired - Fee Related
- 2014-09-29 JP JP2014198604A patent/JP2015028062A/ja active Pending
-
2015
- 2015-10-30 JP JP2015214045A patent/JP2016053057A/ja active Pending
-
2016
- 2016-12-02 US US15/368,016 patent/US20170079978A1/en not_active Abandoned
-
2017
- 2017-02-28 JP JP2017035751A patent/JP2017145251A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016053057A5 (enExample) | ||
| Pelletier et al. | Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys | |
| JP2018507244A5 (enExample) | ||
| EP4054556A4 (en) | SODIUM-GLUCOSE TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY FAILURE, HYPERTENSION AND HEART FAILURE IN PETS | |
| HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
| JP2014513089A5 (enExample) | ||
| AR063155A1 (es) | Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| KR20180018695A (ko) | 항암제 | |
| Farsang | Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk | |
| Cheung et al. | Managing blood pressure control in Asian patients: safety and efficacy of losartan | |
| Tanios et al. | Emerging therapies for diabetic nephropathy patients: beyond blockade of the renin-angiotensin system | |
| Borghi et al. | Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril | |
| IT1401284B1 (it) | Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system). | |
| JP2016520135A5 (enExample) | ||
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| de Zeeuw | Targeting proteinuria as a valid surrogate for individualized kidney protective therapy | |
| Briasoulis et al. | The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control | |
| Barrios et al. | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? | |
| Rastogi et al. | New agents in treatment of hyperkalemia: an opportunity to optimize use of RAAS inhibitors for blood pressure control and organ protection in patients with chronic kidney disease | |
| López et al. | Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients | |
| Lisauskienė et al. | Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012 | |
| Vítovec et al. | Fixní kombinace telmisartanu a thiazidového diuretika v léčbě hypertenze | |
| Cice et al. | The uraemic hypertensive patient: a therapeutic challenge—right you are (if you think so) | |
| Jayaram et al. | DIABETIC NEPHROPATHY: MEANS OF PHARMACOLOGICAL INTERVENTION |